GoAI
Get started
OrbusNeich Medical Group Holdings Limited logo

OrbusNeich Medical Group Holdings Limited

6929.HK

HKSEHealthcareMedical - Instruments & Supplies

Open in GoAI

Latest quote

HK$3.94

−HK$0.095 · -2.35%

Aug 24, 4:08 PM HKT

6929.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The company boasts a significant international presence, serving markets across Japan, Europe, the Middle East, Africa, the Asia Pacific region, the People's Republic of China, and the United States. Its product offerings encompass a range of essential devices, including semi-compliant and scoring balloons used for initial vessel preparation, coronary stents for implantation, non-compliant balloons designed for post-dilatation, and a variety of specialized catheters. This extensive portfolio of products addresses critical steps within percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Founded in 2001, the company is headquartered in Shatin, Hong Kong, and operates as a subsidiary of Harmony Tree Limited.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
HK
CEO
David Chien
Listed since
Dec 23, 2022
Employees
1,528

Market position

Day range

Current HK$3.94

52-week range

Current HK$3.94

Open
HK$4.05
Previous close
HK$4.035
Volume
164K
0.96× average
Average volume
171.5K
Average daily volume
Market cap
3.24B HKD
Beta
-0.64
Market reference 1
50-day average
HK$3.8166
+3.23% above average
200-day average
HK$3.8637
+1.97% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
168.78M USD
P/E (TTM)
9.38×
P/B (TTM)
0.99×
P/S (TTM)
2.12×
EV / EBITDA
3.95×
Earnings yield
10.92%
Free cash flow yield
0.30%
Dividend yield
6.85%

Profitability & efficiency

Gross margin
68.60%
Operating margin
22.64%
Net margin
22.33%
Return on equity
10.15%
Return on assets
9.25%
Return on invested capital
8.37%

Financial health

Debt / equity
0.02×
Current ratio
10.54×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends77%48%18%-11%Gross margin, FY2021: 69.70%Gross margin, FY2022: 67.57%Gross margin, FY2023: 69.22%Gross margin, FY2024: 69.76%Gross margin, FY2025: 67.85%Operating margin, FY2021: 16.69%Operating margin, FY2022: 15.40%Operating margin, FY2023: 25.96%Operating margin, FY2024: 19.63%Operating margin, FY2025: 22.02%Net margin, FY2021: -3.82%Net margin, FY2022: 13.51%Net margin, FY2023: 29.29%Net margin, FY2024: 24.20%Net margin, FY2025: 23.22%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 69.70%. Gross margin FY2022 67.57%. Gross margin FY2023 69.22%. Gross margin FY2024 69.76%. Gross margin FY2025 67.85%. Operating margin FY2021 16.69%. Operating margin FY2022 15.40%. Operating margin FY2023 25.96%. Operating margin FY2024 19.63%. Operating margin FY2025 22.02%. Net margin FY2021 -3.82%. Net margin FY2022 13.51%. Net margin FY2023 29.29%. Net margin FY2024 24.20%. Net margin FY2025 23.22%.

Income trends

Revenue

180.45M USD+9.97%

Operating income

39.74M USD+23.36%

Net income

41.9M USD+5.49%
Income trends across reported periods198.94M USD124.98M USD51.03M USD−22.93M USDRevenue, FY2021: 116.46M USDRevenue, FY2022: 136.82M USDRevenue, FY2023: 153.87M USDRevenue, FY2024: 164.1M USDRevenue, FY2025: 180.45M USDOperating income, FY2021: 19.44M USDOperating income, FY2022: 21.07M USDOperating income, FY2023: 39.94M USDOperating income, FY2024: 32.21M USDOperating income, FY2025: 39.74M USDNet income, FY2021: −4.44M USDNet income, FY2022: 18.49M USDNet income, FY2023: 45.07M USDNet income, FY2024: 39.72M USDNet income, FY2025: 41.9M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 116.46M USD. Revenue FY2022 136.82M USD. Revenue FY2023 153.87M USD. Revenue FY2024 164.1M USD. Revenue FY2025 180.45M USD. Operating income FY2021 19.44M USD. Operating income FY2022 21.07M USD. Operating income FY2023 39.94M USD. Operating income FY2024 32.21M USD. Operating income FY2025 39.74M USD. Net income FY2021 −4.44M USD. Net income FY2022 18.49M USD. Net income FY2023 45.07M USD. Net income FY2024 39.72M USD. Net income FY2025 41.9M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue180.45M USD164.1M USD153.87M USD136.82M USD116.46M USD
Cost of goods sold58.02M USD49.63M USD47.37M USD44.37M USD35.29M USD
Gross profit122.43M USD114.47M USD106.5M USD92.46M USD81.17M USD
Research and development16.18M USD17.05M USD14.81M USD14.5M USD12.15M USD
Selling, general, and administrative67.38M USD62.7M USD54.84M USD55.13M USD50.06M USD
Operating expenses82.69M USD82.26M USD66.56M USD71.39M USD61.73M USD
Interest income8.86M USD11.92M USD10.67M USD2.39M USD12K USD
Interest expense168K USD219K USD142K USD1.46M USD5.61M USD
Depreciation and amortization3.44M USD1.94M USD4.21M USD3.88M USD4.02M USD
Operating income39.74M USD32.21M USD39.94M USD21.07M USD19.44M USD
Net income41.9M USD39.72M USD45.07M USD18.49M USD−4.44M USD

Company facts updated Aug 24, 2026.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.25

2025 complete year+150.0% since 2024

2026 partial: HK$0.12

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Sep 18, 2026

HK$0.08

Quarterly

Record Sep 22, 2026 · Payment Oct 6, 2026

Dividend

Ex-dividend Jun 10, 2026

HK$0.12

Annual

Record Jun 12, 2026 · Payment Jun 26, 2026

Dividend

Ex-dividend Sep 18, 2025

HK$0.15

Special

Record Sep 22, 2025 · Payment Oct 6, 2025

Dividend

Ex-dividend May 29, 2025

HK$0.10

Annual

Record Jun 2, 2025 · Payment Jun 16, 2025

Dividend

Ex-dividend Jun 11, 2024

HK$0.10

Annual

6929.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

ETFs holding 6929.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Dimensional - International Small Cap ETF logoDimensional - International Small Cap ETFDFIS
Market value
19.3K
Weight
0.00%
AUM
5.91B USD
Expense ratio
0.39%
Price / 1D
$37.445-0.27%
Dimensional - International Core Equity 2 ETF logoDimensional - International Core Equity 2 ETFDFIC
Market value
10.81K
Weight
0.00%
AUM
15.43B USD
Expense ratio
0.22%
Price / 1D
$39.295-0.29%

Continue in GoAI

Research 6929.HK

research.disclaimer